Extended-Release, Once-Daily Tramadol Now Available

Posted by Administrator on February 24th, 2006 — in Ultram News

RARITAN, N.J., and TORONTO, Canada, Feb. 21 /PRNewswire/ — A new prescription option is now available to the more than 50 million Americans who suffer from moderate to moderately severe chronic pain. Ortho-McNeil, Inc. and Biovail Corporation (NYSE:BVF) today announced that once-daily ULTRAM(R) ER (tramadol HCl) extended-release tablets are now available by prescription in the […]

DOV Pharmaceutical Announces Statistically Significant Analgesic Effects Of Bicifadine In Phase III Clinical Trial In Patients Following Bunionectomy Surgery

Posted by Administrator on February 24th, 2006 — in Ultram News

HACKENSACK, N.J., Sept. 12 /PRNewswire-FirstCall/ — DOV Pharmaceutical, Inc. announced today that bicifadine, its novel non-narcotic and non-NSAID analgesic, provided statistically and clinically significant analgesic effects at 400 mg administered three times daily (t.i.d) relative to a placebo control group. These effects were comparable to the analgesia produced by the active-control tramadol 100 mg t.i.d. […]

Health Stocks in Motion

Posted by Administrator on February 24th, 2006 — in Ultram News

Shares of Biovail (BVF:NYSE - news - research - Cramer’s Take) were among the best-performing health-related stocks Friday, rising 21% after the company said the Food and Drug Administration approved its Tramadol ER painkiller.
The painkiller was approved for the treatment of moderate to moderately severe chronic pain in 100 milligram, 200 milligram and 300 […]

Old, new post-shingles medication work

Posted by Administrator on February 2nd, 2006 — in Ultram News

A review of the treatments used in treating post-shingles pain concludes older treatments are just as effective as newer ones.
The review showed long-established treatments such as tricyclic antidepressants and some opioids are as effective as newer drugs such as gabapentin, tramadol, and pregabalin, and supports the use of tricyclic […]

Ultram NDA Review

Posted by Administrator on February 2nd, 2006 — in Ultram News

LAVAL, QC, Nov. 30 /PRNewswire-FirstCall/ — Labopharm Inc. (TSX:DDS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its once-daily formulation of the analgesic ultram. Labopharm is seeking regulatory approval to market its once-daily ultram for the management of moderate to moderately severe pain. […]

Sativex blamed, but what about these medicines

Posted by Administrator on February 2nd, 2006 — in Ultram News

With reference to the previous article, other medicines this lady had taken include:
tramadol,
Side effects - Headache, Blurred vision, Dry mouth, Changes in mood, Slow, shallow breathing (respiratory depression), Confusion, Sweating, Nightmares, Muscle weakness, Disturbances of the gut such as diarrhoea, constipation, nausea, vomiting or abdominal pain, False perceptions of things that are not really […]

Generic Equivalent of Ultracet Granted Final Approval by FDA

Posted by Administrator on February 2nd, 2006 — in Ultram News

DETROIT, Dec. 19 /PRNewswire-FirstCall/ — Caraco Pharmaceutical Laboratories, Ltd., (AMEX:CPD) announced today that the US Food and Drug Administration (FDA) have granted final approval for the Company’s Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride with Acetaminophen Tablets.
Caraco’s Tramadol Hydrochloride (HCl) with Acetaminophen Tablets is the generic equivalent of Ortho-McNeil Pharmaceutical Inc. brand product, Ultracet(R), […]